UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform [Yahoo! Finance]
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Yahoo! Finance
a Buy rating and a $35 price target, citing the company's transition from a China-centric commercial strategy to a global innovation powerhouse. The firm views Zai Lab Limited (NASDAQ:ZLAB) as a distinct biopharma platform poised for long-term global expansion by leveraging its strong China-based business while developing a pipeline of fully owned cancer and immunology assets. According to UBS, the global pipeline indicates a trend toward high-value, innovative treatments that address numerous unmet needs, potentially redefining Zai Lab's development path over the coming decade. The bank believes that Zai Lab Limited (NASDAQ:ZLAB) is undervalued, given recent China commercial disappointments, and that the market doesn't provide enough credit to its global pipeline, which UBS claims produces considerable long-term value for investors. Zai Lab Limited (NASDAQ:ZLAB) is a commercial-stage biopharmaceutical company based in China and the United States. It is focused on discovering, d
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Zai Lab (NASDAQ:ZLAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $46.00 to $39.00. They now have an "overweight" rating on the stock.MarketBeat
- ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025 [Seeking Alpha]Seeking Alpha
- Zai Lab (NASDAQ:ZLAB) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Zai Lab (NASDAQ:ZLAB) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Zai Lab (NASDAQ:ZLAB) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.MarketBeat
ZLAB
Earnings
- 11/6/25 - Miss
ZLAB
Sec Filings
- 2/5/26 - Form SCHEDULE
- 1/2/26 - Form 4
- 12/31/25 - Form 144
- ZLAB's page on the SEC website